Patents by Inventor Zhedong Yuan
Zhedong Yuan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11512085Abstract: The present invention provides a class of novel compounds having Btk selective inhibitory activity, better metabolic stability and the like.Type: GrantFiled: December 22, 2019Date of Patent: November 29, 2022Assignee: SHANGHAI DUDE MEDICAL TECHNOLOGY CO., LTDInventors: Xin Liu, Zhedong Yuan, Rui Kong, Shan Chen
-
Publication number: 20200123156Abstract: The present invention provides a class of novel compounds having Btk selective inhibitory activity, better metabolic stability and the like.Type: ApplicationFiled: December 22, 2019Publication date: April 23, 2020Inventors: Xin LIU, Zhedong YUAN, Rui KONG, Shan CHEN
-
Patent number: 10112901Abstract: Disclosed are a method for preparing a dabigatran etexilate intermediate, and an intermediate compound. The method for preparing a dabigatran etexilate intermediate 4 comprises: reacting a compound 3 with a C1-C3 alkyl alcohol solution of methylamine in an organic solvent, wherein, X=chlorine, bromine, or iodine. Also disclosed are an intermediate compound 3 and a preparation method thereof. The method for preparing a dabigatran etexilate intermediate of the present invention has the advantages of simple process, easy operation, high yield, and easy purification, thus being suitable for industrial production.Type: GrantFiled: July 3, 2014Date of Patent: October 30, 2018Assignees: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY, CHINA STATE INSTITUTE OF PHARMACEUTICAL INDUSTRY, CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.Inventors: Yajun Guo, Hanbin Shan, Xueyan Zhu, Zhedong Yuan, Xiong Yu, Meng Guo, Mingtong Hu, Duzheng Wang, Yu Huang
-
Publication number: 20170190666Abstract: Disclosed are a method for preparing a dabigatran etexilate intermediate, and an intermediate compound. The method for preparing a dabigatran etexilate intermediate 4 comprises; reacting a compound 3 with a C1-C3 alkyl alcohol solution of methylamine in an organic solvent, wherein, X=chlorine, bromine, or iodine. Also disclosed are an intermediate compound 3 and a preparation method thereof. The method for preparing a dabigatran etexilate intermediate of the present invention has the advantages of simple process, easy operation, high yield, and easy purification, thus being suitable for industrial production.Type: ApplicationFiled: July 3, 2014Publication date: July 6, 2017Inventors: Yajun GUO, Hanbin SHAN, Xueyan ZHU, Zhedong YUAN, Xiong YU, Meng GUO, Mingtong HU, Duzheng WANG
-
Patent number: 9527803Abstract: The present invention provides a new crystalline form VII of agomelatine, its method of preparation, application and pharmaceutical composition. This new crystalline form offers high purity, a stable crystalline structure and good reproducibility, while its method of production lends itself well to large scale production. In terms of stability and purity, it is superior to the numerous crystalline forms which have hitherto been reported. As a result, the crystalline form VII of the present invention possesses advantages in pharmaceutical preparation.Type: GrantFiled: March 22, 2012Date of Patent: December 27, 2016Assignees: LES LABORATOIRES SERVIER, SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRYInventors: Yu Huang, Ling Tong, Xueyan Zhu, Hanbin Shan, Zhedong Yuan, Xiong Yu
-
Patent number: 9434760Abstract: Provided are a compound of formula (I), pharmaceutically acceptable salts thereof, preparation methods and applications thereof for inhibiting thrombin, and applications in the treatment and prevention of thrombin-mediated and thrombin-related diseases.Type: GrantFiled: November 4, 2011Date of Patent: September 6, 2016Assignee: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRYInventors: Min Li, Hanbin Shan, Yu Huang, Zhedong Yuan, Xiong Yu
-
Patent number: 8829039Abstract: Disclosed are dihydroindolone compounds which can modulate the activity of protein tyrosine kinases, a method for preparing the same, and pharmaceutical compositions comprising the same. Also disclosed are use of such compounds and pharmaceutical compositions thereof in the treatment and/or prophylaxis of protein tyrosine kinase associated diseases in an organism, particularly in the treatment and/or prophylaxis of tumors and fibroblast proliferation associated diseases.Type: GrantFiled: May 25, 2009Date of Patent: September 9, 2014Assignees: Shanghai Institute of Pharmaceutical Industry, Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd.Inventors: Zhedong Yuan, Xiaomin Zhang, Hubo Wang, Xueyan Zhu, Hongjiang Xu, Hui Fu, Wei Song
-
Patent number: 8779199Abstract: The present invention relates to the intermediate compounds for preparation of agomelatine, as well as the preparation methods thereof The intermediate of the present invention for preparation of agomelatine is compound A as shown in the following formula. Also provided are two novel intermediate compounds. When we use these new intermediate compounds to prepare agomelatine, it is simple to manipulate, well-controlled and with high purity, without complicated operations such as rectification and column chromatography separation, and suitable for industrial production. Meanwhile, the preparation methods of the two new intermediates themselves is simple and high yield, only using the most commonly-used 7-methoxy-tetralone as original starting material and undergoing one step of reaction to obtain the intermediates, followed by one more step of converting the intermediate compounds to desired product agomelatine.Type: GrantFiled: June 8, 2011Date of Patent: July 15, 2014Assignee: Les Laboratoires ServierInventors: Peng Zhang, Yu Huang, Zhedong Yuan, Hanbin Shan, Xiong Yu
-
Patent number: 8772488Abstract: The present application discloses crystals of 2-acetoxy-5-(?-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrobromate, crystal compositions and pharmaceutical compositions comprising them and their use. The crystals of prasugrel hydrobromate of the present application possess excellent stability and solubility.Type: GrantFiled: March 31, 2010Date of Patent: July 8, 2014Assignees: Shanghai Institute of Pharmaceutical Industry, Chia Tai Tianqing Pharmaceutical Group Co., LtdInventors: Zhedong Yuan, Xingdong Cheng, Yulei Yang, Ling Tong, Xiong Yu, Laifang Zhang, Wenliang Zhou
-
Patent number: 8729131Abstract: The present invention relates to an agomelatine hydrochloride hydrate of formula I, preparation and use thereof, and to pharmaceutical composition containing it. The agomelatine hydrohalide hydrate obtained through the present method has significant increased solubility than agomelatine, and therefore is more suitable for manufacturing pharmaceutical formulations. In addition, the product enjoys higher stability and purity. Using the present method, product of high purity can be obtained through a simple process, free of any complicated steps. wherein X is Cl.Type: GrantFiled: March 17, 2011Date of Patent: May 20, 2014Assignee: Les Laboratoires ServierInventors: Hanbin Shan, Zhedong Yuan, Xueyan Zhu, Peng Zhang, Hongjuan Pan, Xiong Yu
-
Patent number: 8729132Abstract: The present invention relates to an agomelatine hydrobromide hydrate of formula I wherein X is Br, preparation and use thereof, and to pharmaceutical compositions containing it. The agomelatine hydrobromide hydrate obtained through the present method has significant increased solubility than agomelatine, and therefore is more suitable for manufacturing pharmaceutical formulations. In addition, the product enjoys higher stability and purity. Using the present method, product of high purity can be obtained through a simple process, free of any complicated steps.Type: GrantFiled: March 17, 2011Date of Patent: May 20, 2014Assignee: Les Laboratoires ServierInventors: Hanbin Shan, Zhedong Yuan, Xueyan Zhu, Peng Zhang, Hongjuan Pan, Xiong Yu
-
Publication number: 20140088197Abstract: The present invention provides a mixed crystalline form VIII of agomelatine, its method of preparation, application and pharmaceutical composition. The said mixed crystal consists mainly of crystalline form VI of agomelatine. The said mixed crystalline form is stable and has good reproducibility. Through stability tests, it has been found to be superior to the crystalline form VI in terms of stability. As a result, the crystalline form VIII of the present invention possesses advantages in pharmaceutical preparation.Type: ApplicationFiled: March 22, 2012Publication date: March 27, 2014Applicant: LES LABORATORIES SERVIERInventors: Yu Huang, QING Long, Xueyan Zhu, Hanbin Shan, Zhedong Yuan, Xiong Yu
-
Publication number: 20140011883Abstract: The present invention provides a new crystalline form VII of agomelatine, its method of preparation, application and pharmaceutical composition. This new crystalline form offers high purity, a stable crystalline structure and good reproducibility, while its method of production lends itself well to large scale production. In terms of stability and purity, it is superior to the numerous crystalline forms which have hitherto been reported. As a result, the crystalline form VII of the present invention possesses advantages in pharmaceutical preparation.Type: ApplicationFiled: March 22, 2012Publication date: January 9, 2014Applicants: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY, LES LABORATOIRES SERVIERInventors: Yu Huang, Ling Tong, Xueyan Zhu, Hanbin Shan, Zhedong Yuan, Xiong Yu
-
Patent number: 8614251Abstract: The invention provides a new crystalline form of agomelatine, preparation and use thereof. The X-ray powder diffraction diagram of the agomelatine crystalline form shows main peaks at the diffraction angles 2? 11.13°, 11.82°, 17.49°, 18.29°, 19.48°, 19.72°, 20.50°, 21.76°, 22.54°, 22.97°, 24.56°, 25.36°, 27.16° and 31.93°. Said new crystalline form is characterized by high purity, stability and good reproducibility, and thus is advantageous for the pharmaceutical formulation. In addition, the stability and solubility of said crystalline form are also superior over the several existing crystalline forms.Type: GrantFiled: March 9, 2010Date of Patent: December 24, 2013Assignee: Les Laboratories ServierInventors: Hanbin Shan, Peng Zhang, Zhedong Yuan, Xudong Jiang, Yu Huang, Hubo Wang, Xufeng Cao, Xingdong Cheng, Xiong Yu
-
Publication number: 20130296245Abstract: Provided are a compound of formula (I), pharmaceutically acceptable salts thereof, preparation methods and applications thereof for inhibiting thrombin, and applications in the treatment and prevention of thrombin-mediated and thrombin-related diseases.Type: ApplicationFiled: November 14, 2011Publication date: November 7, 2013Inventors: Min Li, Hanbin Shan, Yu Huang, Zhedong Yuan, Xiong Yu
-
Publication number: 20130267738Abstract: The present invention relates to the intermediate compounds for preparation of agomelatine, as well as the preparation methods thereof. The intermediate of the present invention for preparation of agomelatine is compound A as shown in the following formula. Also provided are two novel intermediate compounds. When we use these new intermediate compounds to prepare agomelatine, it is simple to manipulate, well-controlled and with high purity, without complicated operations such as rectification and column chromatography separation, and suitable for industrial production. Meanwhile, the preparation methods of the two new intermediates themselves is simple and high yield, only using the most commonly-used 7-methoxy-tetralone as original starting material and undergoing one step of reaction to obtain the intermediates, followed by one more step of converting the intermediate compounds to desired product agomelatine.Type: ApplicationFiled: June 8, 2011Publication date: October 10, 2013Applicant: LES LABORATORIES SERVIERInventors: Peng Zhang, Yu Huang, Zhedong Yuan, Hanbin Shan, Xiong Yu
-
Patent number: 8524949Abstract: The present invention relates to a complex of agomelatine and to preparation thereof. The hydrogen halide complex of agomelatine obtained through the present method is more soluble, more stable, and of higher purity than agomelatine itself, making it more suitable to be used in pharmaceutical preparation. Using this method, product of high purity can be obtained through a simple process, without having to incur further complicated steps.Type: GrantFiled: February 26, 2010Date of Patent: September 3, 2013Assignee: Les Laboratories ServierInventors: Hanbin Shan, Peng Zhang, Zhedong Yuan, Xudong Jiang, Yu Huang, Hubo Wang, Xufeng Cao, Xingdong Cheng, Hongjuan Pan, Xiong Yu
-
Publication number: 20130012592Abstract: The present invention relates to an agomelatine hydrobromide hydrate of formula I wherein X is Br, preparation and use thereof, and to pharmaceutical compositions containing it. The agomelatine hydrobromide hydrate obtained through the present method has significant increased solubility than agomelatine, and therefore is more suitable for manufacturing pharmaceutical formulations. In addition, the product enjoys higher stability and purity. Using the present method, product of high purity can be obtained through a simple process, free of any complicated steps.Type: ApplicationFiled: March 17, 2011Publication date: January 10, 2013Applicant: Les Laboratoires ServierInventors: Hanbin Shan, Zhedong Yuan, Xueyan Zhu, Peng Zhang, Hongjuan Pan, Xiong Yu
-
Publication number: 20130005820Abstract: The present invention relates to an agomelatine hydrochloride hydrate of formula I, preparation and use thereof, and to pharmaceutical composition containing it. The agomelatine hydrohalide hydrate obtained through the present method has significant increased solubility than agomelatine, and therefore is more suitable for manufacturing pharmaceutical formulations. In addition, the product enjoys higher stability and purity. Using the present method, product of high purity can be obtained through a simple process, free of any complicated steps. wherein X is Cl.Type: ApplicationFiled: March 17, 2011Publication date: January 3, 2013Applicant: LES LABORATOIRES SERVIERInventors: Hanbin Shan, Zhedong Yuan, Xueyan Zhu, Peng Zhang, Hongjuan Pan, Xiong Yu
-
Publication number: 20120095035Abstract: The present application discloses crystals of 2-acetoxy-5-(?-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrobromate, crystal compositions and pharmaceutical compositions comprising them and their use. The crystals of prasugrel hydrobromate of the present application possess excellent stability and solubility.Type: ApplicationFiled: March 31, 2010Publication date: April 19, 2012Applicants: NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRYInventors: Zhedong Yuan, Xingdong Cheng, Yulei Yang, Ling Tong, Xiong Yu, Laifang Zhang, Wenliang Zhou